Previously Published on Fiercebiotech.com – Just a week after Vertex’s stem cell therapy to treat type 1 diabetes was released from an FDA clinical hold, the company is clearing out potential competition by buying ViaCyte for $320 million. The all-cash deal announced Monday throws a net around ViaCyte’s stem cell-based treatment for type 1 diabetes, which has…
Previously Published on Diabetes Daily ViaCyte Interview By Christine Fallabel – I recently had the opportunity to sit down with Manasi Sinha Jaiman, M.D., M.P.H., Vice President of Clinical Development, and Mark Daniels, Senior Director of Clinical Development, of ViaCyte, “a regenerative medicine company focused on delivering novel stem cell-derived cell replacement therapies as a functional cure for all…
Medical device company Viacyte has developed a device called PEC-Direct that can protect stem cells to be able to live inside the body, produce insulin as needed and possibly cure type 1 diabetes (T1D). Stem cells are placed into PEC-Direct and take three months to become functioning islet cells. Viacyte recently implanted the device into two…
Diabetes Cure News! Johnson & Johnson is joining forces with biotech company ViaCyte to speed development of the first stem cell treatment that could fix and essentially cure the life-threatening hormonal disorder type 1 diabetes. ViaCyte has already begun testing the device in a small number of diabetic patients. If it works as well in…